The Promise of Combining Cancer Vaccine and Checkpoint Blockade for Treating HPV-Related Cancer
Although human papillomavirus (HPV) strains had previously been described in the literature, the earliest published evidence of the link between HPV and cervical cancer dates to 1983 by Harald zur Hausen and colleagues [1]. Since then, over 200 HPV genotypes have been described [2], and the 2008 Nobel Prize was awarded to zur Hausen for his pioneering work in the field. HPV is a common virus that is efficiently transmitted by sexual exposure and skin-to-skin contact [2]. Certain genotypes of HPV (HPV 16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, and 68) are categorized as high-risk (HR) due to their causative association with not only cervical disease (cervical intraepithelial neoplasia [CIN] and cervical cancer), but also penile, anal, vulvar, vaginal, oropharyngeal, and laryngeal precancers or cancers [3,4].
Source: Cancer Treatment Reviews - Category: Cancer & Oncology Authors: Takeo Shibata, Benjamin J. Lieblong, Toshiyuki Sasagawa, Mayumi Nakagawa Tags: Anti-Tumour Treatment Source Type: research
More News: Cancer | Cancer & Oncology | Cancer Vaccines | Cervical Cancer | Cervical Cancer Vaccine | Genital Warts | Human Papillomavirus (HPV) | Laryngeal Cancer | Oropharyngeal Cancer | Penile Cancer | Skin | Vaccines